Television, the drug of the nation


What are the 10 most heavily advertised pharmaceuticals on US television? 

New data published on US industry website Fierce Pharma shows the increasing level of spending by pharmaceutical manufacturers on television advertising in that country.

The report found that spending on the top 10 brands reached US$1.19 billion (A$1.58bn) for the calendar year to 30 September, a 12% increase over the US$1.07 billion (A$1.42 bn) spent so far last year.

Total spending across the 70 or so pharma brands that bought any national TV time this year also saw double-digit growth. Those brands together spent US$2.81 billion (A$3.97 billion), up 11% over last year.

So what were the top 10 brands for TV spend? They were: (listed with their monthly spend for September 2018, compared to August)

  1. Humira (adalimumab), AbbVie anti-inflammatory drug. Total estimated spending: $26.5 million (up from $25.9 million in August)
  2. Lyrica (pregabalin), Pfizer seizure and pain drug. Total estimated spending: $21.2 million (up from $20.6 million in August)
  3. Eliquis (apixaban), Pfizer and Bristol-Myers Squibb anticoagulant (up from 8). Total estimated spending: $17.4 million (up from $9 million in August)
  4. Trulicity (dulaglutide), Eli Lilly GLP-1 diabetes drug (up from 5). Total estimated spending: $12.7 million (up from $14.9 million in August)
  5. Xeljanz (tofacitinib), Pfizer oral rheumatoid arthritis therapy (down from 3). Total estimated spending: $12.1 million (down from $17.7 million in August)
  6. Truvada (emtricitabine/tenofovir), Gilead’s HIV and PrEP drug (new to the list). Total estimated spending: $10.44 million
  7. Vraylar (cariprazine), Allergan antipsychotic drug (new to the list). Total estimated spending: $10.43 million
  8. Otezla (apremilast), Celgene’s oral treatment for plaque psoriasis (down from 7). Total estimated spending: $9.8 million (down from $12.4 million in August)
  9. Jardiance (empagliflozin), Eli Lilly and Boehringer Ingelheim SGLT2 diabetes treatment. Total estimated spending: $9.3 million (up from $8.7 million in August)
  10. Xarelto (rivaroxaban), Johnson & Johnson anticoagulant (down from 6). Total estimated spending: $9 million (down from $12.9 million in August)

Previous Testing for true allergy
Next A matter of life and death

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.